Category Archives: TNF antagonists

Golimumab (Simponi) side effects: risk of serious fungal infections

Centocor Ortho Biotech and FDA reminded prescribers of the risk of serious fungal infections associated with TNF-α blockers, this includes the newer Simponi (golimumab).

Simponi is a recently approved human monoclonal antibody for the treatment of rheumatic diseases. Its indications include:

  • Moderately to severely active Rheumatoid Arthritis (RA) in adults, in combination with methotrexate.
  • Active Psoriatic Arthritis (PsA) in adults, alone or in combination with methotrexate.
  • Active Ankylosing Spondylitis in adults (AS).

According to the FDA, histoplasmosis and other invasive fungal infections are not consistently recognized in patients under other TNF-α blockers such as Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab). This has resulted in delays in appropriate antifungal treatment, which in some cases has lead to death. The agency also added  a Boxed Warning to this group of medications,  alerting about an increased risk of  lymphoma.

Also, the UK’s National Institute for Health and Clinical Excellence (NICE) issued in February 2009 an update of the rheumatoid arthritis clinical guidelines.

Source

MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Simponi (golimumab)

Video lecture: Biologic therapies for inflammatory and autoimmune diseases

Dr. Chan explains how biologic therapy (mainly through monoclonal antibodies) is changing the present and future of autoimmune and inflammatory diseases. He illustrates some examples of autoimmune diseases such as: multiple sclerosis, asthma, treatment of rheumatoid arthritis with etanercept, and others.Continue Reading

Scottish Medicines Consortium accepted Adalimumab (Humira) for adolescents that do not respond to other DMARDs

An excerpt from the Drug Advice issued by the Scottish Medicines Consortium on adalimumab (Humira): adalimumab (Humira)  is  accepted  for  restricted  use  in  NHS  Scotland,  in  combination  with methotrexate, for the treatment of active polyarticular juvenile idiopathic arthritis in adolescents aged 13-17  years  who  have  an  inadequate  response  to  one  or more  disease-modifying  anti-rheumatic drugs…

Are you a visual learner interested in learning psychopharmacology? Click here to get our videos